A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma (Q44635871)

4 December 2017

title

A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma (English)

1 reference

4 December 2017

1 reference

1 reference

Ji-Youn Han

1

1 reference

4 December 2017

Dae Ho Lee

2

1 reference

4 December 2017

Hae Young Kim

3

1 reference

4 December 2017

Eun Kyung Hong

4

1 reference

4 December 2017

Sung Min Yoon

5

1 reference

4 December 2017

Jong Ho Chun

6

1 reference

4 December 2017

Hong Gi Lee

7

1 reference

4 December 2017

Sung Young Lee

8

1 reference

4 December 2017

Eun Hee Shin

9

1 reference

4 December 2017

Jin Soo Lee

10

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

4 December 2017

1 reference

4 December 2017

volume

98

1 reference

4 December 2017

issue

9

1 reference

4 December 2017

page(s)

1918-1924

1 reference

4 December 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Present and future treatment of advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Combination chemotherapy without cisplatin in the treatment of advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11738

7 January 2021

Identifiers

DOI

10.1002/CNCR.11738

1 reference

4 December 2017

1 reference